Nortriptyline (בארץ NORTYLIN) was effective in increasing smoking cessation rates, according to the results of a randomized trial reported in the August issue of Chest.
“This study showed that nortriptyline significantly increases the smoking cessation rate in chronic smokers, as compared to the placebo group, without any significant side effects,” write Celia L. Da Costa, MD, and colleagues from the A.C. Camargo Cancer Hospital in Sao Paulo, Brazil. During six consecutive weeks, 144 patients who were trying to quit smoking were randomized to receive nortriptyline, 75 mg/day, or placebo.
All patients attended behavioral group orientation for five weeks. Smoking cessation rate was 55.9% in the nortriptyline group and 23.3% in the placebo group (P<.001). Univariate analysis revealed that factors predicting smoking cessation were a Fagerstrom test score of less than 7, suggesting low nicotine dependence (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.47 to 6.7; P=.003), and the use of nortriptyline (OR, 4.1; 95% CI, 2 to 8.3;
P<.001).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!